Analysts Set DRI Healthcare Trust (TSE:DHT.UN) Price Target at C$21.83

Shares of DRI Healthcare Trust (TSE:DHT.UN) have earned an average recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is C$21.83.

DHT.UN has been the topic of several analyst reports. Scotiabank lifted their target price on DRI Healthcare Trust from C$22.00 to C$24.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. CIBC lifted their target price on DRI Healthcare Trust from C$19.00 to C$19.50 and gave the company an “outperform” rating in a research report on Friday, March 1st. Stifel Nicolaus lifted their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company a “buy” rating in a research report on Friday, March 1st. National Bankshares boosted their price objective on DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Finally, Raymond James raised DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from C$22.00 to C$24.00 in a research report on Friday, March 1st.

DRI Healthcare Trust Stock Performance

Shares of TSE:DHT.UN opened at C$16.84 on Wednesday. DRI Healthcare Trust has a 12-month low of C$7.55 and a 12-month high of C$17.43. The firm’s 50 day moving average is C$15.75.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.